| Type | Title | Date Released | |
|---|---|---|---|
6-K | Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial in Knee Osteoarthritis | ||
6-K | Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Knee Osteoarthritis | ||
6-K | Enlivex Receives Nasdaq Delisting Notice and Plans Appeal, Effects 1-for-16 Reverse Share Split | ||
6-K | Enlivex Announces 1-for-16 Reverse Share Split | ||
6-K | Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Knee Osteoarthritis | ||
6-K/A | Shareholders to Vote on 1-for-13 to 1-for-16 Reverse Split and Potential Additional Splits to Maintain Nasdaq Listing Compliance | ||
6-K/A | Shareholders Asked to Approve 1-for-16 Reverse Share Split to Maintain Nasdaq Listing Compliance at October 14 Meeting | ||
6-K | Enlivex Ltd. Announces Extraordinary General Meeting of Shareholders for October 14, 2026, to Vote on 1-for-16 Reverse Share Split | ||
6-K | Enlivex Ltd. Reports Second Quarter and Six-Month 2026 Financial Results Highlighted by Digital Asset Treasury Strategy | ||
6-K | Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens | ||
424B3 | Form 424B3 | ||
EFFECT | Form EFFECT |
